Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab-Reference-Cited by-同舟云学术

Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab

Published:2022-10 Issue:1 Volume:160 Page:221-231
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Lu Guangrong,Zhu Ping,Rao Mayank,Linendoll Nadine,Buja L. Maximilian,Bhattacharjee Meenakshi B.,Brown Robert E.,Ballester Leomar Y.,Tian Xuejun,Pilichowska Monika,Wu Julian K.,Hergenroeder Georgene W.,Glass Williams F.,Chen Lei,Zhang Rongzhen,Pillai Anil K.,Hunter Robert L.,Zhu Jay-Jiguang^ORCID

Funder

Dr. Marnie Rose Foundation

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Neurology (clinical),Neurology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11060-022-04144-y.pdf

Reference34 articles.

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

2. Liau LM, Ashkan K, Tran DD et al (2018) First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med 16:142

3. Zhu P, Du XL, Lu G et al (2017) Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: a population-based study. Oncotarget 8:44015–44031

4. Stupp R, Taillibert S, Kanner A et al (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318:2306–2316

5. Seystahl K, Wick W, Weller M (2016) Therapeutic options in recurrent glioblastoma–An update. Crit Rev Oncol Hematol 99:389–408

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Study of Postmortem MRI and Pathological Findings in Malignant Brain Tumors;Cureus;2024-03-15

2. Larotrectinib versus infigratinib for adult patients with both glioma and tyrosine kinase alterations after failure of initial therapies: Efficacy and safety analysis;Clinics;2024-01

3. Multiple therapeutic approaches of glioblastoma multiforme: From terminal to therapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-07